枸地氯雷他定片和依巴斯汀片治疗慢性特发性荨麻疹疗效对比研究.docVIP

枸地氯雷他定片和依巴斯汀片治疗慢性特发性荨麻疹疗效对比研究 　　摘 要：目的：探讨枸地氯雷他定片和依巴斯汀片治疗慢性特发性荨麻疹的临床疗效及安全性。方法：选取我院皮肤科2014年1月至2014年6月慢性特发性荨麻疹的门诊患者82例，按照不同给药方法随机分为治疗组35例和对照组32例，2组均给予常规治疗的同时，治疗组给予枸地氯雷他定片口服治疗，每日一次，每次8.8mg。对照组给予依巴斯汀片口服治疗，每日一次，每次10mg，疗程均为2周，复查后观察两组患者的治疗情况和不良反应发生情况。结果：治疗20天后，观察组显效率及总有效率（42.8%，88.57%）均显著高于对照组（25%，59.38%）（P0.05），与治疗前比较，两组治疗后症状有明显改善，差异分别有统计学意义 （P0.05）；治疗7d、14d后，两组瘙痒、风团SSRI较治疗前分别有统计学意义（P 0.05）；治疗14d后治疗组瘙痒SSRI和风团SSRI较对照组差异分别有统计学意义（P 0.05）。结论：枸地氯雷他定片和依巴斯汀片均可安全、有效缓解慢性特发性荨麻疹症状，但使用枸地氯雷他定片缓解慢性特发性荨麻疹症状快，治疗效果更理想。 　　关键词： 枸地氯雷他定片； 依巴斯汀片； 慢性特发性荨麻疹 　　Abstract：Objective： To investigate theclinical efficacy and safety of Loratadine TabletsandEbastine Tabletsin treatment of chronic idiopathic urticaria.Methods： FromJanuary 2014 to June2014，according to the different？methods of administration， 67 cases of chronicidiopathic urticariapatients in Department of Dermatology in our hospitalwere randomly divided？into treatment group 35 cases and controlgroup of 32 cases，the treatment group patients were givenDesloratadine Citrate Disodium Tabletsoraltherapy，each time 8.8mg a day.The control group patients were givenEbastine Tabletsorally，oncedaily，10mg each time.Each group patients were treated for 2 weeks， theclinical efficacy andadverse reactions were observed of the twogroups of patientsoccurred.Results： 20 days after treatment，the effective rate and total effective rate（42.8%，88.57%） of observation group were markedlyhigher than the control group（25%，59.38%）（P0.05），compared with those before treatment，the symptoms of two groupshad significantly improved after treatment，the differencewas statistically significant resectively（P0.05）；7d，14d aftertreatment， compared with those before treatment，the pruritus，urticariaSSRIof two groupswere statistically significant resectively（P0.05）； compared with control group，the pruritus，urticariaSSRIof treatmentgroupafter 14dwerestatistically significant differenceresectively （P0.05）.？Conclusion：Desloratadine Citrate Disodium Tabletsand Ebastine Tabletscan sa